Influence of maternal virome and HIV status on infant gut virome, growth and immunity

母体病毒组和 HIV 状态对婴儿肠道病毒组、生长和免疫的影响

基本信息

  • 批准号:
    10267757
  • 负责人:
  • 金额:
    $ 74.56万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-09-21 至 2025-08-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY/ABSTRACT The early life microbiome plays a significant role in health and disease, including immune development and maturation. Maternal microbiota is a major determinant of infant microbiota. Studies investigating maternal- infant microbiota transmission and its consequent influence on infant immunity have focused on the bacterial component. Yet the impact of maternal virome on infant virome is largely unknown, and studies of the virome in early life are limited. Infants born to mothers living with HIV are more vulnerable to diseases, have stunted growth, and have altered immunity, including immune activation, even when they are not infected with HIV themselves. Much work has gone into understanding the reasons for this phenomenon. Given that the enteric virome is expanded in HIV infection, it is not surprising that our preliminary data show that infants born to HIV- infected mothers inherit a wider range of viruses than unexposed infants. Thus, similarly to the bacterial microbiome, the gut virome could also play an important role in modulating immune responsiveness and growth of infants. We hypothesize that the infant enteric virome is vertically transferred, and the expanded enteric virome of infants born to mothers who are HIV-infected leads to accelerated immune ontogeny and activation, which influences the morbidity of infants exposed to HIV. We propose to: 1: Determine the influence of maternal virome on the infant enteric virome and compare the virome succession in infants exposed and unexposed to HIV through the first 9 months of life. The viromes of matched mother- infant pairs will be determined via metagenomic sequencing of nucleic acid isolated from purified viral particles. Maternal fecal and vaginal virome composition will be correlated with that of the infants’ gut in the first week postpartum. The composition of the enteric virome will be compared between infants exposed and unexposed to HIV during the first week, 4, 15 and 36 weeks of life. 2: Evaluate the relationship between the virome and the bacterial microbiota in infant stool. We will assess the relationship between bacteriophage and their bacterial targets longitudinally. 3: Evaluate the relationship between the infant enteric virome and intestinal inflammation, immune ontogeny and linear growth. To test the hypothesis that the expanded enteric virome in uninfected infants exposed to HIV contributes to greater immune diversity in early life, we will longitudinally assess circulating NK and T cell ontogeny using CyTOF analysis over the first 9 months of life. To test whether the virome causes altered immune ontogeny, we will feed infant mice with phages with and without their bacterial hosts and evaluate the effect on immunity. Understanding the factors that shape the infant gut virome and its consequent impact on bacterial microbiota, immune ontogeny and linear growth could facilitate the development of interventions to reduce infant morbidity and mortality, particularly for those who are exposed to HIV.
项目概要/摘要 生命早期微生物组在健康和疾病中发挥着重要作用,包括免疫发育和 成熟。母体微生物群是婴儿微生物群的主要决定因素。研究调查母亲- 婴儿微生物群的传播及其对婴儿免疫力的影响主要集中在细菌上 成分。然而,母体病毒组对婴儿病毒组的影响在很大程度上尚不清楚,并且对病毒组的研究 在生命早期是有限的。感染艾滋病毒的母亲所生的婴儿更容易患病、发育迟缓 生长,并改变了免疫力,包括免疫激活,即使他们没有感染艾滋病毒 他们自己。为了理解这种现象的原因,人们进行了大量的工作。鉴于肠溶 病毒组在艾滋病毒感染中扩大,因此我们的初步数据显示感染艾滋病毒的婴儿并不奇怪 受感染的母亲比未接触病毒的婴儿继承了更广泛的病毒。因此,与细菌类似 微生物组、肠道病毒组也可以在调节免疫反应和 婴儿的成长。我们假设婴儿肠道病毒组是垂直转移的,并且扩展的 感染艾滋病毒的母亲所生婴儿的肠道病毒组会导致免疫个体发育加速, 激活,这会影响暴露于艾滋病毒的婴儿的发病率。我们建议: 1:确定母体病毒组对婴儿肠道病毒组的影响并比较病毒组演替 出生后 9 个月内接触和未接触 HIV 的婴儿。匹配的母亲的病毒组 婴儿对将通过从纯化的病毒颗粒中分离的核酸的宏基因组测序来确定。 母亲粪便和阴道病毒组的组成将与第一周婴儿肠道的病毒组组成相关 产后。将比较暴露和未暴露的婴儿的肠道病毒组的组成 在生命的第一周、第 4 周、第 15 周和第 36 周感染 HIV。 2:评估婴儿粪便中病毒组和细菌微生物群之间的关系。我们将评估 噬菌体与其细菌靶标之间的纵向关系。 3:评估婴儿肠道病毒组与肠道炎症、免疫个体发育的关系 和线性增长。检验以下假设:未受感染的婴儿暴露于 HIV 有助于生命早期更大的免疫多样性,我们将纵向评估循环 NK 和 T 细胞 在生命的前 9 个月内使用 CyTOF 分析进行个体发育。测试病毒组是否导致改变 免疫个体发育,我们将用带有或不带有细菌宿主的噬菌体喂养幼年小鼠,并评估 对免疫力的影响。 了解塑造婴儿肠道病毒组的因素及其对细菌微生物群的影响, 免疫个体发育和线性生长可以促进干预措施的发展,以降低婴儿发病率 和死亡率,特别是对于那些接触艾滋病毒的人来说。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Heather Beryl Jaspan其他文献

Heather Beryl Jaspan的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Heather Beryl Jaspan', 18)}}的其他基金

Penile viral and bacterial microbiome, inflammation and HIV susceptibility
阴茎病毒和细菌微生物组、炎症和艾滋病毒易感性
  • 批准号:
    10402631
  • 财政年份:
    2022
  • 资助金额:
    $ 74.56万
  • 项目类别:
Penile viral and bacterial microbiome, inflammation and HIV susceptibility
阴茎病毒和细菌微生物组、炎症和艾滋病毒易感性
  • 批准号:
    10646217
  • 财政年份:
    2022
  • 资助金额:
    $ 74.56万
  • 项目类别:
Bifidobacterium infantis supplementation in early life to improve immunity in infants exposed to HIV: a randomized, placebo-controlled, double-blind trial
生命早期补充婴儿双歧杆菌可提高感染 HIV 的婴儿的免疫力:一项随机、安慰剂对照、双盲试验
  • 批准号:
    10481469
  • 财政年份:
    2022
  • 资助金额:
    $ 74.56万
  • 项目类别:
Bifidobacterium infantis supplementation in early life to improve immunity in infants exposed to HIV: a randomized, placebo-controlled, double-blind trial
生命早期补充婴儿双歧杆菌可提高感染 HIV 的婴儿的免疫力:一项随机、安慰剂对照、双盲试验
  • 批准号:
    10632103
  • 财政年份:
    2022
  • 资助金额:
    $ 74.56万
  • 项目类别:
Influence of HIV infection on vaginal virome and risk of preterm birth in pregnant South African women
HIV 感染对南非孕妇阴道病毒组和早产风险的影响
  • 批准号:
    10325550
  • 财政年份:
    2021
  • 资助金额:
    $ 74.56万
  • 项目类别:
Influence of HIV infection on vaginal virome and risk of preterm birth in pregnant South African women
HIV 感染对南非孕妇阴道病毒组和早产风险的影响
  • 批准号:
    10667617
  • 财政年份:
    2021
  • 资助金额:
    $ 74.56万
  • 项目类别:
Combination biomarkers for preventing HIV and adverse birth outcomes in a South African pregnancy cohort: implications for infant health
在南非妊娠队列中预防艾滋病毒和不良出生结局的组合生物标志物:对婴儿健康的影响
  • 批准号:
    9983241
  • 财政年份:
    2020
  • 资助金额:
    $ 74.56万
  • 项目类别:
Combination biomarkers for preventing HIV and adverse birth outcomes in a South African pregnancy cohort: implications for infant health
在南非妊娠队列中预防艾滋病毒和不良出生结局的组合生物标志物:对婴儿健康的影响
  • 批准号:
    10382303
  • 财政年份:
    2020
  • 资助金额:
    $ 74.56万
  • 项目类别:
Influence of maternal virome and HIV status on infant gut virome, growth and immunity
母体病毒组和 HIV 状态对婴儿肠道病毒组、生长和免疫的影响
  • 批准号:
    10693179
  • 财政年份:
    2020
  • 资助金额:
    $ 74.56万
  • 项目类别:
Influence of maternal virome and HIV status on infant gut virome, growth and immunity
母体病毒组和 HIV 状态对婴儿肠道病毒组、生长和免疫的影响
  • 批准号:
    10161590
  • 财政年份:
    2020
  • 资助金额:
    $ 74.56万
  • 项目类别:

相似海外基金

Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
  • 批准号:
    23K08213
  • 财政年份:
    2023
  • 资助金额:
    $ 74.56万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
  • 批准号:
    2881726
  • 财政年份:
    2023
  • 资助金额:
    $ 74.56万
  • 项目类别:
    Studentship
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
  • 批准号:
    10735090
  • 财政年份:
    2023
  • 资助金额:
    $ 74.56万
  • 项目类别:
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
  • 批准号:
    10722146
  • 财政年份:
    2023
  • 资助金额:
    $ 74.56万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 74.56万
  • 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
  • 批准号:
    10935776
  • 财政年份:
    2023
  • 资助金额:
    $ 74.56万
  • 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
  • 批准号:
    10935796
  • 财政年份:
    2023
  • 资助金额:
    $ 74.56万
  • 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
  • 批准号:
    10935775
  • 财政年份:
    2023
  • 资助金额:
    $ 74.56万
  • 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
  • 批准号:
    10735964
  • 财政年份:
    2023
  • 资助金额:
    $ 74.56万
  • 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
  • 批准号:
    10649041
  • 财政年份:
    2023
  • 资助金额:
    $ 74.56万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了